1 / 44

Global Distribution of HCV Infection

Global Distribution of HCV Infection. HCV Disease Burden Modeling. HCV Disease Progression. Acute Hepatitis. Spontaneously Cured. Chronic Hepatitis – F0. Chronic Hepatitis – F1. Chronic Hepatitis – F2. Chronic Hepatitis – F3. Compensated Cirrhosis. Hepatocellular Carcinoma.

bidelia-davitt
Télécharger la présentation

Global Distribution of HCV Infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Distribution of HCV Infection

  2. HCV Disease Burden Modeling

  3. HCV Disease Progression Acute Hepatitis Spontaneously Cured Chronic Hepatitis – F0 Chronic Hepatitis – F1 Chronic Hepatitis – F2 Chronic Hepatitis – F3 Compensated Cirrhosis Hepatocellular Carcinoma Decompensated Cirrhosis Liver Related Death Liver Transplantation Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59.

  4. HCV Disease Progression Modeling Acute HCV Infection Spontaneously Cured F0 – New Cases (NC) F1 (NC) F2 (NC) F3 (NC) Comp Cirrhosis (NC) F0 – Total Cases (TC) F1 (TC) F2 (TC) F3 (TC) Comp. Cirrhosis (TC) Background Mortality + Cured Diuretic Sensitive Ascites (NC) Variceal Hemorrhage (NC) Hepatic Encephal. (NC) Hepatocellular Carcinoma (NC) Diuretic Sensitive Ascites (TC) Variceal Hemorrhage (TC) Hepatic Encephal. (TC) Hepatocellular Carcinoma (TC) Refractory Ascites (NC) Liver Transplantation Liver Related Mortality Refractory Ascites (TC)

  5. HCV Disease Burden Model Characteristics Easy to use platform – Excel based model Transparent – All formulas are unprotected and visible Ties to historical data – Published data is used to calibrate the model up to 2013 Measures the impact of future decisions – Interface to input potential strategies

  6. The epidemiology of hepatitis C can be explained using a leaky bucket as an analogy New HCV Infections At any point in time, the total number of individuals infected with HCV can be explained by the number of new infections, cured, and mortality since the beginning of time. Cured Mortality

  7. HCV Disease Burden – A Comparison

  8. Viremic HCV prevalence, 1950-2030 Germany, England, France and Spain Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  9. Viremic HCV prevalence, 1950-2030 Brazil, Egypt, Australia and Turkey Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  10. Age distribution, 2013Germany, England, France and Spain Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  11. Age distribution, 2013 Brazil, Egypt, Australia and Turkey Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  12. HCC, decompensated cirrhosis and transplant, 1950-2030Germany, England, France and Spain Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  13. HCC, decompensated cirrhosis and transplant, 1950-2030Brazil, Egypt, Australia and Turkey Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. J Viral Hepat 2014;21 Suppl 1:34-59.

  14. Estimated viremic infections, 2013-2030Germany, England, France and Spain Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  15. Estimated viremic infections, 2013-2030Brazil, Egypt, Australia and Turkey Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  16. Cirrhosis, 2013-2030Germany, England, France and Spain Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  17. Cirrhosis, 2013-2030Brazil, Egypt, Australia and Turkey Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  18. HCC, 2013-2030Germany, England, France and Spain Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  19. HCC, 2013-2030Brazil, Egypt, Australia and Turkey Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  20. Liver-related deaths, 2013-2030Germany, England, France and Spain Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  21. Liver-related deaths, 2013-2030Brazil, Egypt, Australia and Turkey Wedemeyer H, Duberg AS, Buti M, et al. J Viral Hepat 2014; 21 Suppl 1: 60-89.

  22. Historical distribution by age and gender Germany, England, France and Spain Bruggmann P, Berg T, Ovrehus AL, et al. J Viral Hepat 2014; 21 Suppl 1: 5-33.

  23. Historical distribution by age and gender Brazil, Egypt, Australia and Turkey Bruggmann P, Berg T, Ovrehus AL, et al. J Viral Hepat 2014; 21 Suppl 1: 5-33.

  24. HCV Prevalence

  25. Anti-HCV prevalence(Data Quality) Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  26. Anti-HCV Prevalence (Reported) Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  27. Anti-HCV Prevalence (Reported + Extrapolated) Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  28. Viremic HCV Prevalence(Reported) Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  29. Viremic HCV Prevalence(Reported + Extrapolated) Prevalence (Viremic) 0.0%-0.6% 0.6%-0.8% 0.8%-1.3% Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014) 1.3%-2.9% 2.9%-7.8%

  30. Total Viremic HCV Infections (Reported + Extrapolated) Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  31. HCV Viremic Infections(Prevalence & Total Infected) Total Infected (Viremic) Prevalence (Viremic) 0-200K 0.0%-0.6% 200K-650K 0.6%-0.8% 650K-1.9M 0.8%-1.3% Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014) 1.9M-3.5M 1.3%-2.9% 3.5M-9.2M 2.9%-7.8%

  32. Total Viremic HCV InfectionsCountries Responsible for 80% of Global Infections Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  33. HCV Genotype Distribution

  34. Genotype Distribution, by Global Burden of Disease (GBD) Region Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  35. HCV Genotype Distribution Globally Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)

  36. Genotype Distribution by World Bank Regions Razavi H, Gower E, Estes C, Hindman S. Global HCV Genotypes. Poster presented at: The Liver Meeting 2013; 2013 Nov 1-5; Washington, DC, United States.

  37. Genotype Distribution by Region Europe, Western Asia Pacific, High Income Asia, Central Europe, Central Europe, Eastern Asia, South North America Caribbean Asia, Southeast Asia, East Latin America, Central Latin America, Tropical Australasia Sub-Saharan Africa, West Latin America, Southern Latin America, Andean North Africa/Middle East Sub-S Africa, Central Sub-S Africa, Southern Razavi H, Gower E, Estes C, Hindman S. Global HCV Genotypes. AASLD 2013; 2013 Nov 1-5; Washington, DC, United States.

  38. Genotype Distribution by Region Europe, Western Asia Pacific, High Income Asia, Central Europe, Central Europe, Eastern Asia, South North America Caribbean Asia, Southeast Asia, East Latin America, Central Latin America, Tropical Australasia Sub-Saharan Africa, West Latin America, Southern Latin America, Andean North Africa/Middle East Sub-S Africa, Central Sub-S Africa, Southern Razavi H, Gower E, Estes C, Hindman S. Global HCV Genotypes. AASLD 2013; 2013 Nov 1-5; Washington, DC, United States.

  39. HCV Prevalence and Genotype DistributionEurope Russia Estonia United Kingdom Czech Republic Hungary Lithuania Latvia Ireland Denmark Finland Norway Poland Sweden Slovakia Netherlands Belgium Luxembourg Belarus Germany Romania France Serbia Georgia Total Infected (Viremic) Turkey 0-200K 200K-650K 650K-1.9M Armenia 1.9M-3.5M Prevalence (Viremic) Bosnia & Herzegovina 0.0%-0.6% Italy Albania Macedonia Greece Croatia Portugal Spain Slovenia Montenegro 0.6%-0.8% Austria Switzerland 0.8%-1.3% 1.3%-2.9% 2.9%-7.8% Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Journal of Hepatology (2014)

  40. HCV Prevalence and Genotype DistributionAfrica & Middle East Israel Morocco Libya Palestine Lebanon Jordan Kuwait Iraq Algeria Egypt Tunisia Syria Iran Gambia GuineaBissau Saudi Arabia UAE Burkina Faso Ghana Ethiopia Nigeria EquatorialGuinea Central African Republic Gabon Total Infected (Viremic) Prevalence (Viremic) Madagascar 0-200K 0.0%-0.6% 200K-650K South Africa 0.6%-0.8% Congo 650K-1.9M Mozambique 0.8%-1.3% 1.9M-3.5M 1.3%-2.9% 3.5M-9.2M 2.9%-7.8% Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Journal of Hepatology (2014)

  41. HCV Prevalence and Genotype DistributionCentral Asia, South East Asia & Australia Pacific Tajikistan Mongolia Prevalence (Viremic) Uzbekistan Japan 0.0%-0.6% 0.6%-0.8% 0.8%-1.3% 1.3%-2.9% Hong Kong Pakistan 2.9%-7.8% Total Infected (Viremic) 0-200K 200K-650K Korea India 650K-1.9M 1.9M-3.5M 3.5M-9.2M China Sri Lanka New Zealand Vietnam Myanmar Thailand Philippines Taiwan Cambodia Indonesia Malaysia Laos Australia Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Journal of Hepatology (2014)

  42. HCV Prevalence and Genotype DistributionLatin America Dominican Republic Cuba Mexico Puerto Rico Venezuela Colombia Brazil Peru Total Infected (Viremic) 0-200K 200K-650K Prevalence (Viremic) Chile Argentina 650K-1.9M 0.0%-0.6% 0.6%-0.8% 0.8%-1.3% 1.3%-2.9% 2.9%-7.8% Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Journal of Hepatology (2014)

  43. HCV Treatment Rate

  44. Treatment Rate, by Country, 2013 Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21 Suppl 1:34-59. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm – J Viral Hepat 2014. Submitted for publication 30 July 2014.

More Related